Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.

Li L, Sun R, Miao Y, Tran T, Adams L, Roscoe N, Xu B, Manyam GC, Tan X, Zhang H, Xiao M, Tzankov A, Visco C, Dybkaer K, Bhagat G, Tam W, Hsi ED, van Krieken JH, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Zhang M, Winter JN, Medeiros LJ, Rassidakis GZ, Vaupel CA, Li Y, Dakappagari N, Xu-Monette ZY, Young KH.

Mod Pathol. 2019 Jun;32(6):741-754. doi: 10.1038/s41379-018-0193-5. Epub 2019 Jan 21.

PMID:
30666052
2.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.

Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N.

Clin Cancer Res. 2018 Nov 1;24(21):5250-5260. doi: 10.1158/1078-0432.CCR-18-0309. Epub 2018 Jul 18.

PMID:
30021908
3.

Recommendations for clinical biomarker specimen preservation and stability assessments.

Dakappagari N, Zhang H, Stephen L, Amaravadi L, Khan MU.

Bioanalysis. 2017 Apr;9(8):643-653. doi: 10.4155/bio-2017-0009. Epub 2017 May 15. Review.

4.

Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling.

Siska PJ, Johnpulle RAN, Zhou A, Bordeaux J, Kim JY, Dabbas B, Dakappagari N, Rathmell JC, Rathmell WK, Morgans AK, Balko JM, Johnson DB.

Oncoimmunology. 2017 Mar 20;6(4):e1305535. doi: 10.1080/2162402X.2017.1305535. eCollection 2017.

5.

Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors.

Hong D, Said R, Falchook G, Naing A, Moulder S, Tsimberidou AM, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS.

Clin Cancer Res. 2013 Sep 1;19(17):4824-31. doi: 10.1158/1078-0432.CCR-13-0477. Epub 2013 Jul 19.

6.

CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma.

Dakappagari N, Ho SN, Gascoyne RD, Ranuio J, Weng AP, Tangri S.

Cytometry B Clin Cytom. 2012 Mar;82(2):112-9. doi: 10.1002/cyto.b.20631. Epub 2011 Nov 10.

7.

An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors.

Dakappagari N, Neely L, Tangri S, Lundgren K, Hipolito L, Estrellado A, Burrows F, Zhang H.

Biomarkers. 2010 Feb;15(1):31-8. doi: 10.3109/13547500903261347.

PMID:
19747088
8.

Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy.

Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS.

J Immunol. 2008 Jan 15;180(2):699-705.

9.

In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models.

Kretz-Rommel A, Qin F, Dakappagari N, Torensma R, Faas S, Wu D, Bowdish KS.

J Immunother. 2007 Oct;30(7):715-26.

PMID:
17893564
10.

CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy.

Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, Oltean D, Frederickson S, Maruyama T, Wild MA, Nolan MJ, Wu D, Springhorn J, Bowdish KS.

J Immunol. 2007 May 1;178(9):5595-605.

11.

Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responses.

Dakappagari N, Maruyama T, Renshaw M, Tacken P, Figdor C, Torensma R, Wild MA, Wu D, Bowdish K, Kretz-Rommel A.

J Immunol. 2006 Jan 1;176(1):426-40.

12.

Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-A*201 mice.

Dakappagari NK, Sundaram R, Rawale S, Liner A, Galloway DR, Kaumaya PT.

J Pept Res. 2005 Feb;65(2):189-99.

PMID:
15705163
13.

Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.

Dakappagari NK, Lute KD, Rawale S, Steele JT, Allen SD, Phillips G, Reilly RT, Kaumaya PT.

J Biol Chem. 2005 Jan 7;280(1):54-63. Epub 2004 Oct 26.

14.

Protective efficacy of multiepitope human leukocyte antigen-A*0201 restricted cytotoxic T-lymphocyte peptide construct against challenge with human T-cell lymphotropic virus type 1 Tax recombinant vaccinia virus.

Sundaram R, Lynch MP, Rawale S, Dakappagari N, Young D, Walker CM, Lemonnier F, Jacobson S, Kaumaya PT.

J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1329-39.

PMID:
15483462
15.

A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.

Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT.

J Immunol. 2003 Apr 15;170(8):4242-53.

16.

Synthetic peptides as cancer vaccines.

Sundaram R, Dakappagari NK, Kaumaya PT.

Biopolymers. 2002;66(3):200-16. Review.

PMID:
12385038
17.

Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide.

Frangione-Beebe M, Albrecht B, Dakappagari N, Rose RT, Brooks CL, Schwendeman SP, Lairmore MD, Kaumaya PT.

Vaccine. 2000 Dec 8;19(9-10):1068-81. Erratum in: Vaccine 2001 Jul 16;19(28-29):4087.

PMID:
11137241
18.

Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.

Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT.

Cancer Res. 2000 Jul 15;60(14):3782-9.

19.

Nonsteric factors dominate binding of nitric oxide, azide, imidazole, cyanide, and fluoride to the rhizobial heme-based oxygen sensor FixL.

Winkler WC, Gonzalez G, Wittenberg JB, Hille R, Dakappagari N, Jacob A, Gonzalez LA, Gilles-Gonzalez MA.

Chem Biol. 1996 Oct;3(10):841-50.

Supplemental Content

Loading ...
Support Center